Table 4.

ASFV-G-ΔI177L Licensed Vaccine—Safety Studies.

Clinical Model—Safety
Breed	Age/Weight	Route	N	Immunizing Dose	Observation Period (dpv)	Readouts	Comments
Yorkshire (Y) crossbreed	80–90 lb	IM	10	102 HAD50	28	CS, T	[63]
			5	104 HAD50
			5	106 HAD50
Y × Landrace (L) crossbreed	20–30 kg	IM	5	106 HAD50	28	CS, T	[64]
			25	102.6 HAD50		CS
Vietnamese Mong Cai crossbreed	20–30 kg	IM	5	101 HAD50	28	CS, T
			5	102 HAD50
			5	103 HAD50
			5	104 HAD50
			20	102.6 HAD50		CS
Y × L crossbreed	7–8 wks.	IM	4	102.6 HAD50	28	CS, T, V NS	[64]
		N/A	4	contacts
	10 wks.	IM	50	102.6 HAD50	49	CS, V	field study; 2 doses (D0, 21) [65]
		N/A	10	contacts
	7–8 wks.	IM	10	102.6 HAD50	28	CS, T	2 doses (D0, 14) [65]
			6	103.3 HAD50	14		5× overdose [65]
			14	10.3.6 HAD50			10× overdose [65]
Y × L crossbreed	7–8 wks.	IM	22	102.6 HAD50	28	CS
Vietnamese Mong Cai crossbreed	7 wks.		25				2 doses (D0, 14) [65]
Y × L crossbreed	6–8 wks.	IM	17	102.6 HAD50	28		backpassage/reversion to virulence [65]

Readouts: CS = clinical signs, T = temperature, V = viremia, NS = nasal swab.